Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
TAK
TAK
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TAK News
Zasocitinib Shows Significant Efficacy in Psoriasis Studies
2d ago
Newsfilter
Zasocitinib Shows Significant Efficacy in Psoriasis Studies
2d ago
Yahoo Finance
Takeda Reports Promising Phase 3 Data for Zasocitinib in Psoriasis
1d ago
NASDAQ.COM
Takeda Plans Over ¥200B in Annual Savings by 2028
5d ago
seekingalpha
Weave Bio Forms Strategic Advisory Board to Enhance AI in Regulatory Processes
5d ago
Yahoo Finance
Abivax Plans Fundraising Following Key Trial Data Release
6d ago
CNBC
Takeda Pharmaceutical Plans 400 Layoffs to Boost Profitability
Mar 04 2026
seekingalpha
Rusfertide Shows Significant Improvements in Patient Outcomes for Polycythemia Vera in Pivotal Study
Mar 02 2026
Newsfilter
Keros Therapeutics Initiates DMD Trial and Plans ALS Phase II Discussions
Feb 28 2026
Yahoo Finance
Mental Health Treatment Market Set for Accelerated Growth
Feb 24 2026
PRnewswire
Mental Health Drug Market Set for Accelerated Growth
Feb 24 2026
Newsfilter
Takeda's Entyvio Phase 3 Trial Shows Positive Results
Feb 20 2026
Benzinga
Positive Phase 3 Results for Vedolizumab in Pediatric Ulcerative Colitis
Feb 19 2026
Newsfilter
FDA Grants Breakthrough Therapy Designation for Rybrevant
Feb 18 2026
Benzinga
Next-Gen CNS Assets Attract Investor Interest
Feb 10 2026
PRnewswire
Next-Gen CNS Assets Attract Investor Interest
Feb 10 2026
Newsfilter
Show More News
